IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
Glen Rock, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (œRespireRx or the œCompany), focused on the discovery and development of innovative and...
Enforcement Report for Week of June 28, 2023
The Harvard Drug Group, LLC Issues Voluntary Nationwide Recall of Dronabinol Capsules
The Harvard Drug Group, LLC Issues Voluntary Nationwide Recall of Dronabinol Capsules, USP, 2.5 mg and Ziprasidone Hydrochloride Capsules, 20 mg Due to Label Mix-up
The CBD and THC market is growing rapidly, and many people throughout the United States are now exploring their options to see if they can find a product worth their time. While there is already an abundance of standout CBD and THC products on the market, such as edibles, tinctures, and lotions, customers can now purchase disposable vape pens containing the psychoactive cannabinoid Delta-8 Tetrahydrocannabinol, also known as Delta-8 THC.
Each of these new therapies has a proposed rationale for its utility. Ketamine and its molecular sister esketamine increase the effect of glutamate, the most widespread natural chemical stimulant in the brain. Cannabis binds to a series of receptors for its active ingredients, tetrahydrocannabinol and cannabidiol existent in the brain.
Glen Rock, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that Sleep Review Magazine has published, in its June 13, 2022 edition, a free e-book entitled “How Close Are We to Drug Therapy for Obstructive Sleep Apnea?”, in which it discusses the RespireRx dronabinol OSA program as one of four emerging drug treatments for the treatment of OSA.
BURLINGTON, ON, June 7, 2021 /CNW/ - EmpowerPharm today announced they have been certified to manufacture products containing cannabidiol (CBD) to prescription drug standards – a Canadian first.
Researchers examine the effectiveness of consuming hemp oil extracted from the whole Cannabis plant using a chronic neuropathic pain animal model. Researchers at The University of New Mexico (UNM) showed that legal Cannabis hemp oil reduced mechanical pain sensitivity 10-fold for several hours in mice with chronic post-operative neuropathic pain.